1. Home
  2. SGU vs FBRX Comparison

SGU vs FBRX Comparison

Compare SGU & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SGU

Star Group L.P.

HOLD

Current Price

$12.45

Market Cap

422.1M

ML Signal

HOLD

Logo Forte Biosciences Inc.

FBRX

Forte Biosciences Inc.

HOLD

Current Price

$25.28

Market Cap

379.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SGU
FBRX
Founded
1995
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
422.1M
379.3M
IPO Year
1997
2017

Fundamental Metrics

Financial Performance
Metric
SGU
FBRX
Price
$12.45
$25.28
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$67.00
AVG Volume (30 Days)
24.3K
202.1K
Earning Date
05-06-2026
05-14-2026
Dividend Yield
5.90%
N/A
EPS Growth
N/A
61.30
EPS
N/A
N/A
Revenue
$1,784,418,000.00
$36,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$6.70
N/A
Revenue Growth
1.04
N/A
52 Week Low
$11.31
$4.91
52 Week High
$13.50
$35.62

Technical Indicators

Market Signals
Indicator
SGU
FBRX
Relative Strength Index (RSI) 48.29 44.66
Support Level $12.34 $21.94
Resistance Level $13.11 $31.71
Average True Range (ATR) 0.28 2.73
MACD -0.01 0.04
Stochastic Oscillator 48.77 46.91

Price Performance

Historical Comparison
SGU
FBRX

About SGU Star Group L.P.

Star Group LP is a home heating oil and propane distributor and services provider with one reportable operating segment that principally provides heating related services to residential and commercial customers. It serves residential and commercial customers whose primary use is to heat their homes and buildings in the Northeast and Mid-Atlantic U.S. regions. The company derives the majority of revenue from Petroleum products, which consist of home heating oil and propane as well as diesel fuel and gasoline.

About FBRX Forte Biosciences Inc.

Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).

Share on Social Networks: